



Fax Referral To: 800-323-2445

Phone: 866-278-6634

**Zelboraf<sup>TM</sup> (vemurafenib)**

**Enrollment Form**

**For Blue Cross Blue Shield of Rhode Island Members**

Date: \_\_\_\_\_ Needs by Date (Please Specify): \_\_\_\_\_

Ship to: ☐ Patient ☐ Office ☐ Other: \_\_\_\_\_

**PATIENT INFORMATION**

(Complete the following or send patient demographic sheet)

Patient Name: \_\_\_\_\_  
Address: \_\_\_\_\_  
City, State, Zip: \_\_\_\_\_  
Home Phone: \_\_\_\_\_  
Alternate Phone: \_\_\_\_\_  
Last Four of SS #: \_\_\_\_\_ Primary Language: \_\_\_\_\_  
Insurance ID: \_\_\_\_\_  
Date of Birth: \_\_\_\_\_ Gender: \_\_\_\_\_

**PRESCRIBER INFORMATION**

Prescriber's Name: \_\_\_\_\_  
State License #: \_\_\_\_\_ UPIN: \_\_\_\_\_  
DEA #: \_\_\_\_\_ NPI #: \_\_\_\_\_  
Group or Hospital: \_\_\_\_\_  
Address: \_\_\_\_\_  
City, State Zip: \_\_\_\_\_  
Phone: \_\_\_\_\_ Fax: \_\_\_\_\_  
Contact Person: \_\_\_\_\_  
Contact Phone: \_\_\_\_\_

**INSURANCE INFORMATION** (Please copy and attach the front and back of insurance and prescription drug card)

<b>Prescription Card:</b>	Name of Insurer: _____	ID#: _____	BIN: _____	PCN: _____	Group: _____
<b>Primary Insurance:</b>	Subscriber: _____	ID#: _____	Name of Insurer: Blue Cross Blue Shield of RI	Phone: _____	
<b>Secondary Insurance:</b>	Subscriber: _____	ID#: _____	Name of Insurer: _____	Phone: _____	

**STATEMENT OF MEDICAL NECESSITY for BCBS of Rhode Island Members**

**Diagnosis (ICD-9 Code):** ☐ Malignant melanoma 172 ☐ Other: \_\_\_\_\_ • Date of Diagnosis: \_\_\_\_\_

**APPROVAL CRITERIA: CHECK ALL BOXES THAT APPLY.**

**NOTE: Any areas that are not filled out will be considered not applicable to your patient & MAY AFFECT THE OUTCOME of this request.**

- |  |  |
|--|--|
| • Patient has a diagnosis of unresectable or metastatic melanoma           | <input type="checkbox"/> Yes <input type="checkbox"/> No |
| • Genetic testing was performed for the BRAF V600E mutation                | <input type="checkbox"/> Yes <input type="checkbox"/> No |
| • The Melanoma is BRAF V600E positive                                      | <input type="checkbox"/> Yes <input type="checkbox"/> No |
| • The requested quantity does not exceed 8 tablets per day (240 mg/tablet) | <input type="checkbox"/> Yes <input type="checkbox"/> No |

**PRESCRIPTION INFORMATION**

MEDICATION	STRENGTH	DIRECTIONS	QUANTITY	REFILLS
<input type="checkbox"/> Zelboraf <sup>TM</sup> (vemurafenib)				

X	X
PRODUCT SUBSTITUTION PERMITTED	DISPENSE AS WRITTEN
(Date)	